5 research outputs found
Effect of Background Diuretic Therapy on the Clinical Efficacy of SGLT2 Inhibitors in Patients of Heart Failure with Reduced Ejection Fraction: Current Evidence
No full textSodium-glucose cotransporter-2 (SGLT2) inhibitors are a fundamental therapy for heart failure with reduced ejection fraction(HFrEF). The clinical efficacy of SGLT2 inhibitors in the presence of background diuretic therapy has been questioned, mainlybecause of the overlapping diuretic mechanism of action. However, recently, data analysis from two landmark trials, DELIVERand EMPEROR-Reduced, has attempted to settle this question. Both analyses demonstrate a consistent benefit of SGLT2inhibitors across a wide range of background diuretic therapy. This brief communication sheds light on the key findings fromthese scientific studie
Arrhythmia in Adult Congenital Heart Disease
No full textThis case report highlights the significance of a multidisciplinary approach in the management of patients with repairedmembranous ventricular septal defect (VSD) who develop postoperative arrhythmias. We present the case of a young femalewho experienced symptomatic episodes of supraventricular tachycardia following VSD repair. Through electrophysiologicalstudy and radiofrequency ablation, multiple tachycardia substrates were identified and successfully ablated. This reportunderscores the importance of combining surgical repair, electrophysiological evaluation and intervention to achieve optimaloutcomes in this specific patient population
Iron Deficiency in Heart Failure: Unveiling the Hidden Culprit
No full textIron deficiency (ID) is a frequent comorbidity in patients with heart failure (HF). Coexistent HF and ID make the issuesmore challenging to diagnose and treat. Iron deficiency exacerbates clinical symptoms, impairs quality of life and increasesthe risk of recurrent hospitalization for HF. Conversely, a proinflammatory state and altered gut kinetic in HF may resultin absolute or functional ID, which conventional laboratory makers may not diagnose and differentiate accurately. Noveldiagnostic markers like soluble transferrin receptor (sTfR), reticulocyte hemoglobin concentration, red blood cell distributionwidth, sTfR: log (ferritin) ratio and serum hepcidin levels may help to diagnose ID more accurately in the setting of HF. Theintravenous (IV) iron formulation has shown promising results in improving the functional class and reducing recurrenthospitalization in patients with HF and ID. Futuristic therapies like nanosized iron preparations, hepcidin inhibitors andhepcidin antagonists may help manage ID more efficiently and conveniently in HF. This manuscript explores the relationshipbetween ID and HF. It also provides the latest information related to the diagnosis and treatment of ID in HF patient
Iron Deficiency in Heart Failure: Unveiling the Hidden Culprit
No full textIron deficiency (ID) is a frequent comorbidity in patients with heart failure (HF). Coexistent HF and ID make the issuesmore challenging to diagnose and treat. Iron deficiency exacerbates clinical symptoms, impairs quality of life and increasesthe risk of recurrent hospitalization for HF. Conversely, a proinflammatory state and altered gut kinetic in HF may resultin absolute or functional ID, which conventional laboratory makers may not diagnose and differentiate accurately. Noveldiagnostic markers like soluble transferrin receptor (sTfR), reticulocyte hemoglobin concentration, red blood cell distributionwidth, sTfR: log (ferritin) ratio and serum hepcidin levels may help to diagnose ID more accurately in the setting of HF. Theintravenous (IV) iron formulation has shown promising results in improving the functional class and reducing recurrenthospitalization in patients with HF and ID. Futuristic therapies like nanosized iron preparations, hepcidin inhibitors andhepcidin antagonists may help manage ID more efficiently and conveniently in HF. This manuscript explores the relationshipbetween ID and HF. It also provides the latest information related to the diagnosis and treatment of ID in HF patients
